METHODOLOGICAL DEVELOPMENT OF QUANTITATIVE MRS OF THE BREAST

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 乳腺癌是一种非常常见的疾病，每8名美国女性中就有一人在一生中受到影响，每年导致超过4万人死亡。开发用于筛查、诊断、肿瘤分期和治疗监测的新的非侵入性工具可以帮助提高患者护理的质量。我们小组以前已经证明，定量磁共振波谱可以用来给出肿瘤对治疗的反应的早期迹象。这种方法的临床可行性目前正在进行一项多点临床试验(ACRIN 6657)的研究。 该项目的目标是开发和评估乳腺癌定量磁共振波谱的改进方法。几种新的磁共振波谱技术将被开发出来，并与标准的ACRIN 6657 MRS协议进行比较。 这个项目将分两个阶段进行。第一阶段将在幻影和正常志愿者身上开发和比较这些序列。这一阶段将持续大约6个月，在这一阶段结束时，我们将选择最有希望的序列变体。在这一阶段，我们估计，在20周(30小时)中，我们每周需要一次1.5小时的课程。 在第二阶段，我们将对一系列10个受试者进行正常的重复性研究，每个受试者研究两次。采集方案将包括常规MRI，然后是标准ACRIN 6657 MRS采集，然后是实验性的MRS方法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Breast cancer is a very common disease, affecting 1 in 8 American women in their lifetimes and causing more than 40,000 deaths each year. The development of new non-invasive tools for screening, diagnosis, tumor staging, and treatment monitoring can help improve the quality of patient care. It has been previously shown by our group that quantitative MR spectroscopy can be used to give an early indication of a tumor's response to therapy. The clinical feasibility of this methodology is currently being investigated in a multi-site clinical trial (ACRIN 6657). The goal of this project is to develop and evaluate improved methods for performing quantitative MR spectroscopy in breast cancer. Several new MR spectroscopy techniques will be developed and compared to the standard ACRIN 6657 MRS protocol. There will be two phases to this project. Phase I will develop and compare these sequences on phantoms and normal volunteers. This phase will last approximately 6 months, at the end of which we will select the most promising of the sequence variations. In this phase we estimate that we will need one 1.5-hour session per week for each of 20 weeks (30 hrs). In Phase II, we will perform a normal reproducibility study on a series of 10 subjects, each studied twice. The acquisition protocol will consist of conventional MRI, followed by the standard ACRIN 6657 MRS acquisition, then followed by the experimental MRS methods.